Multiple Myeloma section

Multiple Myeloma News & Features

CD38 Levels Associated With Daratumumab Response in Multiple Myeloma

CD38 Levels Associated With Daratumumab Response in Multiple Myeloma

Response to the human CD38-directed monoclonal antibody daratumumab is significantly associated with CD38 expression on the tumor cells in patients with multiple myeloma, per a recent study.

Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma

Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.

Carfilzomib Increases Survival for Patients With Relapsed Multiple Myeloma

Carfilzomib Increases Survival for Patients With Relapsed Multiple Myeloma

A post-hoc analysis of the Phase 3 ASPIRE study indicates that treatment combining carfilzomib with lenalidomide and dexamethasone extended survival time for patients with multiple myeloma.

Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma

Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma

A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.

Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma

Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma

Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs